Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02679-5
Abstract: CD47, an immune checkpoint receptor frequently unregulated in various blood and solid tumors, interacts with ligand SIPRα on innate immune cells, and conveys a “do not eat me” signal to inhibit macrophage-mediated tumor phagocytosis. This… read more here.
Keywords: cd47; bispecific antibody; cd47 bispecific; activity ... See more keywords
Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
Sign Up to like & getrecommendations! Published in 2023 at "Theranostics"
DOI: 10.7150/thno.79367
Abstract: Background: Even though PD-1/PD-L1 is an identified key “don't find me” signal to active adaptive immune system for cancer treatment, the overall response rate (ORR) for all cancer patients is still limited. Other effective therapeutic… read more here.
Keywords: cd47; cd47 bispecific; cd47 sirp; cancer treatment ... See more keywords